Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Periodontitis Pipeline Review, H2 2016 - Therapeutics Report Detailing 8 Companies & 15 Drug Profiles - Research and Markets

Research and Markets
Posted on: 04 Oct 16

Research and Markets has announced the addition of the "Periodontitis - Pipeline Review, H2 2016" report to their offering.

Periodontitis pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities Institutes.

Periodontitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Periodontitis Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.

The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Periodontitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Periodontitis - Overview
  5. Pipeline Products for Periodontitis - Comparative Analysis
  6. Periodontitis - Therapeutics under Development by Companies
  7. Periodontitis - Therapeutics under Investigation by Universities/Institutes
  8. Periodontitis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Periodontitis - Products under Development by Companies
  13. Periodontitis - Products under Investigation by Universities/Institutes
  14. Periodontitis - Companies Involved in Therapeutics Development
  • Amyndas Pharmaceuticals LLC
  • C3 Jian, Inc
  • CSL Limited
  • Ensol Biosciences Inc.
  • Enzo Biochem, Inc.
  • Geistlich Pharma AG
  • Kaken Pharmaceutical Co., Ltd.
  • TGV-Laboratories

For more information about this report visit

View source version on

Business Wire

Last updated on: 04/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.